The EU Court of Justice upholds the abuse of patent systems and the procedures for marketing pharmaceutical products to prevent or delay the arrival of competing for generic medicinal products on the market for proton pump inhibitors (AstraZeneca)

ECJ rejects appeal relating to abuse of the patent system and the procedures for marketing of drugs* On 6 December 2012, the European Court of Justice (“ECJ”) handed down its ruling rejecting AstraZeneca’s (“AZ”) appeal in relation to the Losec case. In the first instance, the General Court largely upheld the Commission decision which found that AZ abused the patents system and the procedures for marketing pharmaceutical products in order to prevent or delay the arrival of competing generic medicinal products on the market for proton pump inhibitors, such as AZ’s product Losec (See Newsletter 4/2010, p. 6, Newsletter 5/2010, p. 7 and Newsletter 3/2012 p. 9 for additional background information). In its appeal, AZ claimed that lack of transparency was insufficient for a finding of

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Gabriele Accardo, The EU Court of Justice upholds the abuse of patent systems and the procedures for marketing pharmaceutical products to prevent or delay the arrival of competing for generic medicinal products on the market for proton pump inhibitors (AstraZeneca), 6 décembre 2012, e-Competitions December 2012, Art. N° 62394

Visites 215

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues